1. Fig. 1 ZMAb improves survival of EBOV-challenged NHPs
Fig. 1 ZMAb improves survival of EBOV-challenged NHPs. (A) Nine cynomolgus macaques were challenged with 1000 PFU of EBOV (red arrow).
ZMAb improves survival of EBOV-challenged NHPs. (A) Nine cynomolgus macaques were challenged with 1000 PFU of EBOV (red arrow). Two groups (n = 4) were treated with ZMAb beginning either at 24 hours (days 1, 4, and 7; blue arrows) or at 48 hours (days 2, 5, and 8; pink arrows). A control animal (n = 1) received PBS (days 1, 4, and 7). The animals were sampled on treatment days plus days 14 and 21 (black arrows) and examined for (B) serum murine mAb levels by an Ebola virus–like particle (eVLP) ELISA, (C) survival, and (E) viremia measured by real-time RT-PCR (GEQ, genome equivalents) or (F) TCID50. Only PCR-positive samples were assayed for TCID50. (D) Historical cynomolgus macaque controls over the last 2 years, using the same challenge virus stock and dose, are presented with their time to death after challenge. All macaques have consistent symbols across panels.
Xiangguo Qiu et al., Sci Transl Med 2012;4:138ra81
Copyright © 2012, American Association for the Advancement of Science